Text Size

Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting

This study has been completed.
Sponsor:
Collaborator:
Pfizer
Information provided by:
Sarah Cannon Research Institute
ClinicalTrials.gov Identifier:
NCT00877045
First received: April 3, 2009
Last updated: August 3, 2010
Last verified: August 2010
History of Changes
  Purpose

This is a retrospective medical record abstraction to evaluate the patterns of care for Gastrointestinal stromal tumors (GIST) in the community setting. Patient demographics and characteristics along with the treatments received will be described. Investigators will establish the percentage of patients who undergo surgery, the percentage of patients who are treated with kinase inhibitors as well as in what setting (adjuvant or metastatic) as well as the duration of therapy. Physician information will also be collected to assess for differences in treatment based on physician or geographical differences.


Condition
Gastrointestinal Stromal Tumors

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting

Resource links provided by NLM:

MedlinePlus related topics: Cancer
U.S. FDA Resources

Further study details as provided by Sarah Cannon Research Institute:

Enrollment: 200
Study Start Date: January 2008
Study Completion Date: February 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients diagnosed with GIST based on ICD-9 code from January 2005 to present will be eligible. This will include current active patients as well as patients who have expired and have medical chart available. Estimate reviewing approximately 300 charts total.

Criteria

Inclusion Criteria:

  • Patients diagnosed with GIST based on ICD-9 code from January 2005 to present will be eligible. This will include current active patients as well as patients who have expired and have medical chart available.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00877045

Locations
United States, Florida
Florida Cancer Specialists
Fort Myers, Florida, United States, 33901
United States, Georgia
Georgia Cancer Specialists
Atlanta, Georgia, United States, 30341
United States, Tennessee
Chattanooga Oncology Hematology Associates
Chattanooga, Tennessee, United States, 37404
Tennessee Oncology, PLLC
Nashville, Tennessee, United States, 37023
United States, Virginia
Virginia Cancer Institute
Richmond, Virginia, United States, 23235
Sponsors and Collaborators
Sarah Cannon Research Institute
Pfizer
Investigators
Study Chair: Jeffrey F Patton, M.D. Sarah Cannon Research Institute
  More Information

No publications provided

Responsible Party: Jeffrey F. Patton, M.D., SCRI Oncology Research Consortium
ClinicalTrials.gov Identifier: NCT00877045     History of Changes
Other Study ID Numbers: SCRI OUTCOMES 01
Study First Received: April 3, 2009
Last Updated: August 3, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by Sarah Cannon Research Institute:
Gastrointestinal Stromal Tumors
GIST
tyrosine kinase inhibitors
Imatinib
 Gleevec
Suntinib
Sutent

Additional relevant MeSH terms:
Gastrointestinal Stromal Tumors
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
 Neoplasms
Digestive System Diseases
Gastrointestinal Diseases

ClinicalTrials.gov processed this record on May 23, 2013